Plasminogen Activator Inhibitor Type 2 Inhibits Tumor Necrosis Factor α-induced Apoptosis
暂无分享,去创建一个
[1] M. Lanotte,et al. Cleaved intracellular plasminogen activator inhibitor 2 in human myeloleukaemia cells is a marker of apoptosis. , 1994, British Journal of Cancer.
[2] Mark A. Murcko,et al. Structure and mechanism of interleukin-lβ converting enzyme , 1994, Nature.
[3] A. Copeta,et al. Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts. , 1994, Experimental cell research.
[4] L. Tartaglia,et al. Enhanced synthesis of tumor necrosis factor-inducible proteins, plasminogen activator inhibitor-2, manganese superoxide dismutase, and protein 28/5.6, is selectively triggered by the 55-kDa tumor necrosis factor receptor in human melanoma cells. , 1994, Journal of Biological Chemistry.
[5] M. Hendrix,et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. , 1994, Science.
[6] S. Kawabata,et al. A Limulus intracellular coagulation inhibitor with characteristics of the serpin superfamily. Purification, characterization, and cDNA cloning. , 1994, Journal of Biological Chemistry.
[7] Junying Yuan,et al. Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3 , 1993, Cell.
[8] Z. Oltvai,et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.
[9] G. Rossi,et al. Processing of complex between urokinase and its type‐2 inhibitor on the cell surface , 1993, FEBS letters.
[10] Mike Rothe,et al. Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor , 1993, Cell.
[11] W. Fiers,et al. Effect of bcl-2 proto-oncogene expression on cellular sensitivity to tumor necrosis factor-mediated cytotoxicity. , 1993, Oncogene.
[12] T. Hennet,et al. Expression of BCL-2 protein enhances the survival of mouse fibrosarcoid cells in tumor necrosis factor-mediated cytotoxicity. , 1993, Cancer research.
[13] D. Longo,et al. Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin‐1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[14] D. Lomas,et al. Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor. , 1993, The Journal of biological chemistry.
[15] W. Birchmeier,et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. , 1992, The EMBO journal.
[16] P. Gettins,et al. Structure and mechanism of action of serpins. , 1992, Hematology/oncology clinics of North America.
[17] M. Krönke,et al. Human 55-kDa receptor for tumor necrosis factor coupled to signal transduction cascades. , 1992, The Journal of biological chemistry.
[18] R. Black,et al. Viral inhibition of inflammation: Cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme , 1992, Cell.
[19] K. O. Elliston,et al. A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes , 1992, Nature.
[20] J. Dickinson,et al. Control of plasminogen-activator inhibitor type 2 gene expression in the differentiation of monocytic cells. , 1992, European journal of biochemistry.
[21] M. Gyetko,et al. Urokinase expression in mononuclear phagocytes: cytokine‐specific modulation by interferon‐γ and tumor necrosis factor‐α , 1992, Journal of leukocyte biology.
[22] N. Taniguchi,et al. Phorbol ester induces manganese-superoxide dismutase in tumor necrosis factor-resistant cells. , 1991, The Journal of biological chemistry.
[23] C. Baglioni,et al. Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. , 1991, The Journal of biological chemistry.
[24] L. Tartaglia,et al. The two different receptors for tumor necrosis factor mediate distinct cellular responses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[25] Higuchi Masahiro,et al. Tnf-mediated cytotoxicity. importance of intracellular cgmp level for determining tnf-sensitivity☆ , 1991 .
[26] G von Heijne,et al. The efficiency of the uncleaved secretion signal in the plasminogen activator inhibitor type 2 protein can be enhanced by point mutations that increase its hydrophobicity. , 1991, The Journal of biological chemistry.
[27] W. Fiers. Tumor necrosis factor Characterization at the molecular, cellular and in vivo level , 1991, FEBS letters.
[28] Gwyn T. Williams. Programmed cell death: Apoptosis and oncogenesis , 1991, Cell.
[29] E. Kruithof,et al. Plasminogen activator inhibitor-2 in patients with monocytic leukemia. , 1991, Leukemia.
[30] C. Baglioni,et al. Plasminogen activator inhibitor type‐2 Is a major protein induced in human fibroblasts and SK‐MEL‐109 melanoma cells by tumor necrosis factor , 1990, Journal of cellular physiology.
[31] R. Black,et al. Substrate specificity of the protease that processes human interleukin-1 beta. , 1990, The Journal of biological chemistry.
[32] L. Orci,et al. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes , 1990, The Journal of cell biology.
[33] G. Wong,et al. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor , 1989, Cell.
[34] S. T. Howard,et al. Vaccinia virus encodes a family of genes with homology to serine proteinase inhibitors. , 1989, The Journal of general virology.
[35] A. Levinson,et al. Effects of cellular transformation on expression of plasminogen activator inhibitors 1 and 2. Evidence for independent regulation. , 1989, The Journal of biological chemistry.
[36] S. Ho,et al. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. , 1989, Gene.
[37] W. Fiers,et al. Involvement of a serine protease in tumour-necrosis-factor-mediated cytotoxicity. , 1988, European journal of biochemistry.
[38] L. Gooding,et al. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. , 1988, Journal of immunology.
[39] E. Kruithof,et al. Determination of intermediates, products and cleavage site in the reaction between plasminogen activator inhibitor type‐2 and urokinases , 1988, FEBS letters.
[40] Volker Herzog,et al. Establishment of a human cell line (mono mac 6) with characteristics of mature monocytes , 1988, International journal of cancer.
[41] B. Schwartz,et al. Increased release of plasminogen activator inhibitor type 2 accompanies the human mononuclear cell tissue factor response to lipopolysaccharide. , 1988, Blood.
[42] M. Clark,et al. Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[43] R. Carrell,et al. Genetic engineering and the serpins. , 1988, BioEssays : news and reviews in molecular, cellular and developmental biology.
[44] R. Medcalf,et al. Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells , 1987, Molecular and cellular biology.
[45] B. Binder,et al. Proliferation of a human epidermal tumor cell line stimulated by urokinase , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[46] V. Ruggiero,et al. Protection from tumor necrosis factor cytotoxicity by protease inhibitors. , 1987, Cellular Immunology.
[47] D. Belin,et al. Amiloride selectively inhibits the urokinase‐type plasminogen activator , 1987, FEBS letters.
[48] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[49] B. Aggarwal,et al. Effects of growth factors on the antiproliferative activity of tumor necrosis factors. , 1987, Cancer research.
[50] B. Aggarwal,et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. , 1985, Science.
[51] D. Wallach. Preparations of lymphotoxin induce resistance to their own cytotoxic effect. , 1984, Journal of immunology.
[52] R. Stephens,et al. Novel properties of human monocyte plasminogen activator. , 1984, European journal of biochemistry.
[53] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[54] A. Feinberg,et al. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.
[55] A. Wyllie. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation , 1980, Nature.
[56] E. Shaw,et al. The susceptibility of urokinase to affinity labeling by peptides of arginine chloromethyl ketone. , 1979, Biochimica et biophysica acta.
[57] T. Chen,et al. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. , 1977, Experimental cell research.
[58] A. Wyllie,et al. Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.
[59] T. Kawano,et al. Partial purification and properties of urokinase inhibitor from human placenta. , 1970, Journal of biochemistry.
[60] P. Quax,et al. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. , 1994, The American journal of pathology.
[61] P. Vassalli,et al. The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.
[62] D. Belin,et al. Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: a localized and regulated proteolytic system. , 1992, Current topics in microbiology and immunology.
[63] K. Danø,et al. Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.
[64] W. V. Shaw. [57] Chloramphenicol acetyltransferase from chloramphenicol-resistant bacteria , 1975 .